Dexamethasone Efficacy in HELLP I Syndrome

HELLP Syndrome Clinical Trial

Official title: Dexamethasone Efficacy in HELLP I Syndrome, a Multicentric, Double-blind, Placebo-controlled, Randomized Clinical Trial

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine the efficacy of dexamethasone for treatment of HELLP I (hemolysis, elevated liver enzymes and low platelet count) syndrome.

Clinical Trial Description

Treatment of HELLP syndrome usually is restricted to measures of support and treatment of complications. In 2005, in a subgroup analysis we showed that, among patients with HELLP 1, there were a shorter average time to platelet recovery and less duration of hospitalization in women who received dexamethasone therapy, however the importance of this finding is diminished because this was an unplanned analysis and the severity of the disease was not taken into account at randomization. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• HELLP Syndrome
• Syndrome

• NCT number: NCT01138839
• Study type: Interventional
• Source: Universidad del Valle, Colombia
• Contact: Javier Fonseca, Dr
• Phone: 5725583912
• Email: jaenfo@gmail.com
• Status: Recruiting
• Phase: Phase 3
• Start date: October 2009
• Completion date: December 2012